Thats where real progress comes from
Whether retatrutide's glucagon receptor agonism provides additive cardiovascular benefit beyond what GLP-1 and GIP activation deliver is an important question that dedicated cardiovascular outcomes trials (CVOTs) within the TRIUMPH program may eventually answer
Diarrhea affects 12-17% of tirzepatide users
The pancreas typically produces adequate digestive enzymes in patients without pancreatic insufficiency, and GLP-1 receptor agonists do not directly inhibit enzyme synthesis
For weight management, NHS treatment is typically initiated within specialist weight management services, with specific BMI thresholds, comorbidity requirements, and continuation criteria that must be met
Going in the other direction from Foundayo to retatrutide should theoretically work similarly, with the expectation of additional weight loss from the more potent medication